* INVO Bioscience Inc INVO.OQ INVO.O is expected to report
results on November 15.
* The Lakewood Ranch, Florida-based company is expected to
report revenue of $325.5 thousand, according to the mean
estimate from 2 analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for INVO Bioscience Inc is
for a loss of 20 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for INVO Bioscience
Inc is $5.63, about 41.3% above its last closing price
of $3.30.
This summary was machine generated November 12 at 23:32 GMT.
All figures in US dollars unless otherwise stated